Pharmafile Logo

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

March 18, 2024 |  

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

- PMLiVE

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.

Why in-person-only should be a thing of the past

I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:

  • Expensive
  • Associated with a large environmental footprint
  • Inflexible and not accommodating to everyone’s schedules, work or personal commitments, and preferences
  • Susceptible to last-minute no-shows due to flight delays or poor driving conditions

Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:

  • Valuable time wasted on didactic data presentations
  • Very limited “air time” per participant
  • Uneven share of voice, with more extroverted or senior advisors tending to take up more speaking time
  • A tendency for answers to be “knee-jerk reactions” rather than thought-through responses and for people to simply ‘agree’ with others
  • Limited ability to dive deeper into interesting or controversial ideas
  • Suboptimal diversity of advisors due to potential geographic or language barriers

Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…

[Read the full article here]

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Courageous Conversation ep.12: Not Going Back: How COVID Has Changed Clinical Trials

Natalie Yeadon, CEO & Co-Founder at Impetus Digital, provides insight into how COVID has changed clinical trials.

Courageous Conversation ep.11: How to Inspire Creativity with Virtual Working Groups

Natalie Yeadon, Co-Founder & CEO at Impetus Digital, provides insight on how to inspire creativity with virtual working groups.

Parallel HCP-Patient Advisory Boards: A Customer Story

Learn how a Pharma team engaged both dermatologists and patients with psoriasis in two parallel virtual advisory boards.

Courageous Conversation ep.10: Facial Recognition Software in Healthcare

Natalie Yeadon, Co-Founder & CEO at Impetus Digital, provides insight on Facial Recognition Software in Healthcare.

Transforming the Future of Health & Aging from a Global Health & Social Impact Approach

Dr. Zayna Khayat, Future Strategist at SE Health, dives into the future of aging and healthcare in Canada, including the roles of emerging technologies, the shift to people-powered healthcare, and…

Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery

Dr. Shahar Keinan, Co-founder & CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve…

Top-10 ways that Pharma teams can fight the climate crisis

Ten easy steps that individual medical, marketing, clinical, regulatory, and market access teams can take to reduce their own footprints.

Revolutionizing 3D Bioprinting & Disrupting the Drug Development Industry

Christine Whiteside, COO of VoxCell BioInnovation, discusses 3D bioprinting, including current and future applications and key barriers to realizing its full potential. She also shares her tips for getting new…

It Takes 5 to Tango: The 5 Ps in Healthcare

Dr. Verena Voelter, Founder & Managing Director at 5P Health Care Solutions, explores collaborative value-based healthcare models, the role of digital transformation in enabling new forms of patient-centric and value-generating…

Blockchain for Tracking and Validating Medical Cannabis

Robert Galarza, CEO of TruTrace Technologies, Inc., dives into the use of blockchain technology for verifying medical cannabis products and protecting intellectual property. He also shares his leadership tips and…